Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D53YZV
|
|||
| Drug Name |
SAR445877
|
|||
| Drug Type |
Fusion protein
|
|||
| Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 2 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-15 (IL15) | Target Info | . | [2] |
| Programmed cell death protein 1 (PD-1) | Target Info | . | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| TNF signaling pathway | ||||
| Intestinal immune network for IgA production | ||||
| HTLV-I infection | ||||
| Herpes simplex infection | ||||
| Rheumatoid arthritis | ||||
| Cell adhesion molecules (CAMs) | ||||
| T cell receptor signaling pathway | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| FSH Signaling Pathway | ||||
| Leptin Signaling Pathway | ||||
| Panther Pathway | Interleukin signaling pathway | |||
| Reactome | PD-1 signaling | |||
| WikiPathways | Cytokines and Inflammatory Response | |||
| T-Cell Receptor and Co-stimulatory Signaling | ||||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05584670) A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Sanofi | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.